Journal
JOURNAL OF NEUROCHEMISTRY
Volume 162, Issue 1, Pages 24-38Publisher
WILEY
DOI: 10.1111/jnc.15540
Keywords
psychedelics; G protein-coupled receptors (GPCR); serotonin; neurons; special issue
Categories
Ask authors/readers for more resources
A confluence of factors has reignited interest in psychedelic drugs, with the FDA designating psilocybin as a Breakthrough Therapy for treatment-resistant depression. The clearer understanding of how these drugs exert their effects at the molecular level is essential for further development of applications in hallucinogenic and therapeutic mechanisms.
A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the United States Food and Drug Administration's designation of psilocybin as a Breakthrough Therapy for treatment-resistant depression, a new path has been forged for the conveyance of psychedelics to the clinic. Essential to the further development of such applications, however, is a clearer understanding of how these drugs exert their effects at the molecular level. Here we review the current knowledge regarding the molecular details of psychedelic drug actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available